Ronald A. Andrews Jr.
Net Worth

Last updated:

What is Ronald A. Andrews Jr. net worth?

The estimated net worth of Mr. Ronald A. Andrews Jr. is at least $7,904,732 as of 1 Dec 2022. He owns shares worth $1,056,282 as insider and has received compensation worth at least $6,848,450 in OncoCyte Corporation.

What is the salary of Ronald A. Andrews Jr.?

Mr. Ronald A. Andrews Jr. salary is $978,350 per year as Chief Executive Officer, Pres & Director in OncoCyte Corporation.

How old is Ronald A. Andrews Jr.?

Mr. Ronald A. Andrews Jr. is 65 years old, born in 1960.

What stocks does Ronald A. Andrews Jr. currently own?

As insider, Mr. Ronald A. Andrews Jr. owns shares in one company:

Company Title Shares Price per share Total value
OncoCyte Corporation (OCX) Chief Executive Officer, Pres & Director 333,212 $3.17 $1,056,282

What does OncoCyte Corporation do?

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX logo
OCX
OncoCyte Corporation
$3.17

Ronald A. Andrews Jr. insider trading

OncoCyte Corporation

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock, no par value 250,000 N/A N/A
Option
Restricted Stock Units 250,000 N/A N/A
Purchase
Common Stock, no par value 40,000 $0.96 $38,400
Purchase
Common Stock, no par value 50,000 $1.28 $64,150
Option
Common Stock, no par value 65,000 N/A N/A
Option
Restricted Stock Units 65,000 N/A N/A
Option
Common Stock, no par value 106,221 N/A N/A
Option
Restricted Stock Units 106,221 N/A N/A
Purchase
Common Stock, no par value 11,000 N/A N/A
Purchase
Common Stock, no par value 40,000 $1.35 $53,880
Purchase
Common Stock, no par value 18,000 $2,372 $42,696,000
Purchase
Common Stock, no par value 27,216 $2.26 $61,454
Purchase
Common stock, no par value 17,482 N/A N/A

OncoCyte key executives

OncoCyte Corporation executives and other stock owners filed with the SEC: